Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Beta-soluble NSF attachment protein (NAPB)
- Target
- NAPB
- Molecular classification
- SNARE-associated adaptor protein, Intracellular trafficking protein, Vesicular transport protein
01
Overview
Beta-soluble NSF attachment protein (NAPB) is a cytosolic protein specifically expressed in the brain that acts as a co-factor for the N-ethylmaleimide-sensitive factor (NSF) ATPase. NAPB facilitates proper SNARE complex disassembly—critical for synaptic vesicle fusion and neurotransmitter release in neurons. It binds the SNARE complex, allowing NSF to use ATP hydrolysis for recycling SNARE components and maintaining effective synaptic transmission[2][3]. Loss-of-function mutations cause profound effects on neuronal development and maintenance, supporting its key biological role and marking it as a notable therapeutic and diagnostic target for neurological disorders[2]. NAPB is not classically a receptor, enzyme, or ion channel; it is best described as an adaptor protein involved in intracellular vesicle trafficking specific to the nervous system[2][3].
- Other names
- NSF attachment protein betaN-ethylmaleimide-sensitive factor attachment protein betaNAPBSNAP-betaBeta-soluble NSF attachment proteinSNAPBDEE107
02
Mechanism of action
Drugs or inhibitors acting on the SNARE-NSF-NAPB complex typically block, disrupt, or stabilize synaptic transmission by preventing proper SNARE disassembly and recycling, thus modulating neurotransmitter release
03
Biological functions
Synaptic vesicle recyclingSNARE complex disassemblyNeurotransmitter releaseIntracellular membrane fusionNeuronal regulation
04
Disease associations
Neurodevelopmental disorders (e.g., epilepsy, autism spectrum disorder, early-onset epileptic encephalopathy)Potential roles in other neurological and neuropsychiatric disorders
05
Safety considerations
Disrupting NAPB function may lead to severe neurodevelopmental abnormalities, synaptic transmission failure, epileptic encephalopathy, and autismGeneral manipulation of vesicle fusion mechanisms can result in broad neurological dysfunction
06
Interacting drugs
No approved drugs directly targeting NAPB are known as of 2024; it is part of the SNARE pathway which might be modulated indirectly (e.g., by neurotoxins or research inhibitors affecting vesicle fusion)
07
Biomarkers
Loss-of-function mutations of NAPB (e.g., protein truncating or exon-skipping variants) can serve as genetic biomarkers for early-onset epileptic encephalopathies or certain cases of autism
Beyond the preview
Go deeper on Beta-soluble NSF attachment protein (NAPB).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Beta-soluble NSF attachment protein (NAPB).